75.21
+1.08(+1.46%)
Currency In USD
| Previous Close | 74.13 |
| Open | 73.88 |
| Day High | 76.71 |
| Day Low | 72.69 |
| 52-Week High | 103 |
| 52-Week Low | 19.45 |
| Volume | 390,720 |
| Average Volume | 958,961 |
| Market Cap | 5.41B |
| PE | -20.89 |
| EPS | -3.6 |
| Moving Average 50 Days | 72.48 |
| Moving Average 200 Days | 49.96 |
| Change | 1.08 |
If you invested $1000 in Kymera Therapeutics, Inc. (KYMR) since IPO date, it would be worth $2,228.8 as of January 14, 2026 at a share price of $74.13. Whereas If you bought $1000 worth of Kymera Therapeutics, Inc. (KYMR) shares 5 years ago, it would be worth $911.81 as of January 14, 2026 at a share price of $74.13.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
GlobeNewswire Inc.
Yesterday at 12:00 PM GMT
KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial expected to start in 1Q26, with data expected in 2H26 A
Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
GlobeNewswire Inc.
Jan 06, 2026 12:00 PM GMT
WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced tha
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
Dec 11, 2025 9:01 PM GMT
WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the